The function of most amino acid substitutions is largely unknown

Through a massively parallel in-vivo process called the GigaAssay, Heligenics produces a Gene Mutation/Function Library (“GMLs”). Each GML measures the impact of all possible amino acids substitutions in the functional target protein, doing in a short time what would ordinarily take years or even decades to perform.

LEARN MORE

Heligenics answers challenges across three main markets:

Drug Development

Securing an FDA approval of a new drug is a long, arduous, and high-risk process taking many years. Heligenics GMLs improve drug development by improving selection of lead compounds, evaluating analogues, as well as optimizing clinical trial design. Genetic grouping of participants improves the efficacy and safety of a clinical trial, thereby decreasing the risk of drug failure.

Failed Drug Rescue

Almost 90% of drug candidates fail Phase II or III clinical trials, and there is >$1 T invested in failed drug inventory now on the shelves of pharmaceutical companies. With recent advances in precision medicine, 100’s of medicines are genetically targeted. Heligenics functional genetic analysis of drug targets and drugs, combined with population genetics data, reduce the risk of clinical trial failure.

Genetic Testing

Genetic testing is a multibillion-dollar industry and is necessary for both accurate diagnosis of rare disease and effective targeted cancer therapy. Because the clinical impact of only 1% of mutations in cancer genes are known, less than 1/3 of patients receive targeted therapy. Heligenics GMLs help commercial diagnostic laboratories and suppliers better connect their patients with targeted therapies.

Heligenics can comprehensively measure the functional significance of naturally occurring mutations in the human genome, increasing the accuracy of genetic testing (whether for rare disease or cancer), and providing unique solutions for drug development and drug rebirth.
And we can do it in only a few months!

Determine the impact of natural human variation upon your clinical trial

Known risk profiles in the drug development process can be greatly enhanced through identification of key functional genetic variants and amino acid positions. You can identify resistance variants in the human population in advance, or identify substitutions impacting function near your drug binding site. Alleles that produce resistance or toxicity as identified by GMLs can then guide candidate selection, drug derivitization, and trial design.

Enhance your dose-response and toxicity safety studies through identifying key functional genetic variants
Identify variants in your populations that confer resistance
Identify substitutions that impact function near your drug binding site, thus guiding your derivitization process

Rescue a failed drug candidate by discovering underlying genetic variation that impacts efficacy and safety.

Unlock the potential of a previously failed drug through an understanding of underlying genetic variation that could negatively impact safety and efficacy, or identify resistance substitutions or mutations near the drug binding site.

The Variants of Unknown Significance are growing exponentially with detailed analysis of increasing numbers of tumor samples.
Functional determination of key cancer driver gene mutations may provide valuable information for new therapeutic options.

Determine the impact of VUS on the functions of amino acids or promoters

Each Gene Mutation Library measures the impact of all possible amino acid substitutions. For example, one isoform of BRCA1 has 1816 amino acids. To individually test each amino acid substitution by other approaches would be impossible.

You can an expand your genetic test offering beyond single substitutions in coding regions.
You can measure the impact of variation in 5’ promoter regions, 3’ untranslated regions, and even double single nucleotide variants as grouped haplotypes

Research genetic susceptibility to COVID-19 disease

Heligenics can produce Gene Mutation/Function libraries (GML)s for all variants in the promoter and 3’ UTR that affect gene expression and in the coding region that effect binding of SARS-CoV2. These GMLs can be important for understanding COVID-19 pathogenesis and then genetic testing for COVID-19 susceptibility and prognosis.